Nuformix Wins Strong Shareholder Backing as All AGM Resolutions Pass

Nuformix Plc ( (GB:NFX) ) has issued an update.

Nuformix plc reported that all resolutions at its Annual General Meeting were passed by shareholders, confirming strong support for the company’s strategy and governance. Investors approved the annual report and remuneration, reappointed three directors and the auditor, and authorised the board to set audit fees.

Shareholders also backed authorities to allot shares, disapply pre-emption rights, buy back the company’s own shares and call general meetings on 14 days’ notice. The high approval rates across resolutions provide management with financial and operational flexibility as it advances its drug repurposing pipeline in fibrosis and oncology.

The most recent analyst rating on (GB:NFX) stock is a Hold with a £0.26 price target. To see the full list of analyst forecasts on Nuformix Plc stock, see the GB:NFX Stock Forecast page.

Spark’s Take on GB:NFX Stock

According to Spark, TipRanks’ AI Analyst, GB:NFX is a Neutral.

The score is held down primarily by weak financial performance—zero recent revenue, ongoing losses, and persistent negative free cash flow—despite the benefit of no debt. Technicals add downside risk with price below key short/medium-term averages and negative MACD, while valuation is also constrained by a negative P/E and no dividend support.

To see Spark’s full report on GB:NFX stock, click here.

More about Nuformix Plc

Nuformix plc is a UK-listed pharmaceutical development company focused on repurposing drugs to address unmet medical needs in fibrosis and oncology. It leverages expertise in discovering, developing and patenting novel drug forms with improved physical properties to create differentiated products in new indications, aiming to build a pipeline of preclinical assets with strong licensing potential.

Average Trading Volume: 27,202,377

Technical Sentiment Signal: Hold

Current Market Cap: £5.17M

See more data about NFX stock on TipRanks’ Stock Analysis page.